A South Korean company is preparing to sell an injection made from donated human fat, aimed at the sunken cheeks and hollow temples that show up on people who lose weight fast on drugs like Ozempic and Zepbound.

Here is what it actually does. Fat left over from donor tissue is stripped down to its underlying structure — the scaffolding that fat cells normally sit inside — and that scaffold is injected into the face. A patient’s own fat cells then move into the empty framework and grow there, rebuilding volume with the body’s own tissue instead of a synthetic filler that eventually dissolves.

L&C Bio, the Kosdaq-listed biotech behind the product, developed the technology roughly five years ago and holds patents on it in South Korea, the United States and China, chief executive Lee Whan Chul said in an interview. The product carries the working name MegaAdipoECM.

The reason it has not been sold until now had nothing to do with the science. South Korean law classified donated fat as medical waste, which barred companies from reusing it. Lawmakers changed that this year, and L&C Bio expects to launch after a one-year grace period, most likely in late 2027.

The American Hook

The condition the product targets is a byproduct of an American pharmaceutical boom. GLP-1 drugs — Novo Nordisk’s Ozempic and Wegovy, Eli Lilly’s Mounjaro and Zepbound — strip weight quickly, and the face often thins first. The result can include a hollowed-out look, sunken eyes, deeper wrinkles and sagging skin along the jaw and neck. Doctors stress it is a cosmetic effect rather than a medical danger, and that it is not a recognized diagnosis — but it is showing up in dermatology offices in volume.

That has already created a US retail category. Skincare brands have rolled out topical lines aimed at GLP-1 users, though dermatologists are candid that creams cannot put back what was lost. Topicals can improve texture, hydration and collagen density; they cannot restore the fat underneath, which is what creates the hollow cheeks in the first place. That gap — between what a serum can do and what the patient sees in the mirror — is the market L&C Bio is aiming at.

The company also intends to be selling in the United States around the same window. It has said it plans to enter the US market by 2027.

Why the Company Thinks It Will Sell

L&C Bio is not guessing at demand. It already sells a related product built on donated human skin rather than fat.

That product, Re2O, was introduced in late 2024 and runs roughly $400 to $530 per session. The company’s first-quarter operating profit came in at 6 billion won — about $4 million — a jump of more than 900% from a year earlier, and the stock has more than doubled over the past year. In January, Lee said the company was targeting record annual sales of 150 billion won, close to $104 million, with an operating margin above 20%.

Demand has been brisk enough to cause shortages. Shares spiked nearly 30% in a single session last year after a Daegu dermatologist posted that the product had sold out, and the company said the crunch reflected a timing mismatch between clinic inventories and distribution rather than a manufacturing limit.

The company has been pushing the line outward market by market. It launched two versions in Mongolia this spring after regulatory clearance, part of an expansion into Central Asia. Injectable boosters made from donated human tissue have become one of the faster-growing corners of South Korea’s aesthetics business.

The Objection

Injecting material derived from a deceased donor into a healthy person’s face for cosmetic reasons is not a settled question, even in Seoul.

A Korean attorney, Kwon Dongju, has called for banning the cosmetic use of human tissue and wants injectable tissue products reclassified as drugs. L&C Bio argues the donated material is rigorously processed, and points to certification from the Association for Advancing Tissue and Biologics, a Washington-based body, which has said it is not aware of any effect on tissue supply for medical treatment and that donation honors the donor’s wishes.

That regulatory argument will follow the product to the US, where tissue-derived injectables face a stricter and slower approval path than the cosmetic category L&C Bio operates in at home. The Korean law change cleared the way to manufacture. It did not clear the way to sell in America.

Two years remain before the product reaches a clinic anywhere. In the meantime, the weight-loss drugs that created the problem keep adding patients — and the company has effectively made a bet that the aftermath of the injection will be worth as much as the injection itself.

JBizNews Desk | Seoul

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.